Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
275 studies found for:    "Diffuse scleroderma"
Show Display Options
Rank Status Study
21 Unknown  Fractional Carbon Dioxide Laser Versus UVA 1 in Treatment of Localized Scleroderma
Condition: Localized Scleroderma
Interventions: Device: Fractional carbon dioxide laser;   Device: Ultraviolet A1 phototherapy (UVA1)
22 Completed Mycophenolate Mofetil in Systemic Sclerosis
Condition: Diffuse Cutaneous Systemic Sclerosis
Intervention: Drug: Mycophenolate Mofetil
23 Completed An Open-Label Study to Evaluate Biomarkers and Safety in Systemic Sclerosis Patients Treated With ABR-215757 (Paquinimod)
Condition: Systemic Sclerosis
Intervention: Drug: paquinimod
24 Completed Efficacy and Safety Study of GB-0998 for Treatment of Systemic Sclerosis
Condition: Scleroderma, Systemic
Intervention: Drug: High-dose intravenous immunoglobulin (Venoglobulin-IH)
25 Completed Finger Hardness Measure in Scleroderma
Condition: Scleroderma
Intervention:
26 Completed Effectiveness and Safety of Lidocaine for Scleroderma
Condition: Scleroderma
Interventions: Drug: Lidocaine 2% without vessel constrictor;   Other: Placebo - physiological solution 0,9%
27 Withdrawn Scleroderma Treatment With Celution Processed ADRCs Registry
Condition: Scleroderma
Intervention:
28 Unknown  High Dose Intravenous N-Acetylcysteine Versus Iloprost for Early, Rapidly Progressive Diffuse Systemic Sclerosis
Condition: Scleroderma, Diffuse
Intervention: Drug: N-acetylcysteine (NAC)
29 Enrolling by invitation Seoul National University Hospital Systemic Sclerosis Cohort
Condition: Systemic Sclerosis
Intervention: Other: This is an observational prospective study.
30 Recruiting Neuropsychiatric Scleroderma Study: Systematic Evaluation of Neuropsychiatric Involvement in Systemic Sclerosis
Condition: Systemic Sclerosis
Intervention: Other: Magnetic resonance Imaging
31 Withdrawn Low-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe Systemic Sclerosis
Condition: Systemic Scleroderma
Interventions: Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Drug: tacrolimus;   Drug: mycophenolate mofetil;   Biological: rituximab;   Drug: cyclophosphamide;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
32 Recruiting Scleroderma Registry
Conditions: Systemic Sclerosis;   Scleroderma
Intervention:
33 Recruiting A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis
Condition: Diffuse Cutaneous Systemic Sclerosis
Interventions: Drug: Abatacept;   Drug: Placebo
34 Completed Skin Biopsy Specimens as Biomarkers of Systemic Sclerosis and Response to Mycophenolate Mofetil
Condition: Systemic Sclerosis
Intervention:
35 Completed Treatment Outcome in Early Diffuse Cutaneous Systemic Sclerosis
Condition: Early Diffuse Cutaneous Systemic Sclerosis
Interventions: Drug: Methotrexate;   Drug: Mycophenolate mofetil;   Drug: Cyclophosphamide
36 Completed Pharmacokinetics of Oral Treprostinil in Patients With Systemic Sclerosis
Condition: Systemic Sclerosis
Intervention: Drug: treprostinil diethanolamine
37 Unknown  Genetic Study of the FBN1 Gene and Fibrillin-1 Abnormalities in Choctaw Native Americans and Other Patients With Systemic Sclerosis
Condition: Systemic Sclerosis
Intervention:
38 Active, not recruiting Rituximab in Systemic Sclerosis
Condition: Systemic Sclerosis
Interventions: Drug: Rituximab;   Drug: Placebo (NaCl)
39 Completed Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDY
Condition: Systemic Scleroderma
Interventions: Drug: Sildenafil;   Drug: placebo
40 Withdrawn Probiotics in Patients With Moderate-to-severe Distention/ Bloating From Systemic Sclerosis
Condition: Scleroderma
Intervention: Drug: Lactobacillus

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.